chronic kidney disease
Conditions
Interventions
Add oral tolvaptan 15mg/day to the conventional therapy for a week
Add oral furosemide 100mg/day to the conventional therapy for a week
Sponsors
Yokohama City University Medical Center Yokohama City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients have ability to provide written informed consent 2)Patients between 20-85 years of age at the time of enrolling 3)Patients with chronic kidney disease stage 3-5 (eGFR < 60mL/min/1.73m2 ) 4)Patients with heart failure have at least one or more the following body fluid retention symptoms ; pleural effusion / ascites / lower limb edema / blepharedema / pulmonary congestion / juglar venous distention 5)Patients given oral furosemide 20-100mg/day at the time of enrolling
Exclusion criteria
Exclusion criteria: 1)Patients undergoing hemodialysis or peritoneal dialysis during the study period 2)Previous history of tolvaptan use 3)The anuric patients 4)Patients without a sense of thirst 5)Patients without ability to intake water 6)Serum Na >=146mEq/L (within 3 days from a registration day) 7)Patients showing allergy to tolvaptan 8)Other cases which treating physicians regards as inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of urine output | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) serum Cr 2) serum Na 3) body weight 4) symptoms of volume overload 5)the indispensability days untill a discharge | — |
Countries
Japan
Contacts
Public ContactShiro Komiya
Yokohama City University Medical Center Department of Nephrology and Hypertension
Outcome results
None listed